logo.png
CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences
May 22, 2020 08:00 ET | CalciMedica
Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™ LA JOLLA, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc....
logo.png
CalciMedica Announces that FDA Has Strongly Recommended Moving to a Blinded Placebo-controlled Trial with Auxora™ in Patients with Severe COVID-19 Pneumonia
May 21, 2020 08:00 ET | CalciMedica
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC)...
logo.png
CalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy
May 07, 2020 08:00 ET | CalciMedica
LA JOLLA, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC)...
logo.png
CalciMedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical COVID-19 Pneumonia on High-Flow Oxygen Therapy
April 30, 2020 08:00 ET | CalciMedica
Phase 2 open-label study expands to additional sites across the U.S. and aims to enroll 120 patients LA JOLLA, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the...
logo.png
FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND
April 09, 2020 08:00 ET | CalciMedica
Regions Hospital in St. Paul, Minnesota has begun a Phase 2 clinical study of CM4620-IE in patients with severe COVID-19 pneumonia this week, and Henry Ford Hospital in Detroit is expected to begin a...